Lixisenatide as add-on to insulin glargine for the treatment of type 2 diabetes mellitus.
Forst T.
Expert Opin Pharmacother · journal article · DOI 10.1080/14656566.2016.1206079 PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för lixisenatide. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
49 hitsCost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective.
Chuang LH, Verheggen BG, Charokopou M, Gibson D, Grandy S, Kartman B.
J Med Econ · comparative study; journal article · DOI 10.1080/13696998.2016.1203329Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment in Type 2 Diabetes Mellitus: A Post Hoc Analysis.
Ahrén B, Galstyan G, Gautier JF, Giorgino F, Gomez-Peralta F, Krebs M, Nikonova E, Stager W, Vargas-Uricoechea H.
Diabetes Ther · journal article; case-report · DOI 10.1007/s13300-016-0179-6Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial.
Nauck M, Rizzo M, Johnson A, Bosch-Traberg H, Madsen J, Cariou B.
Diabetes Care · randomized controlled trial; journal article · DOI 10.2337/dc15-2479Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial.
Rosenstock J, Diamant M, Aroda VR, Silvestre L, Souhami E, Zhou T, Perfetti R, Fonseca V, LixiLan PoC Study Group.
Diabetes Care · clinical trial, phase ii; comparative study; research-article; randomized controlled trial; journal article · DOI 10.2337/dc16-0046Lixisenatide improves glycemic outcomes of Japanese patients with type 2 diabetes: a meta-analysis.
Seino H, Onishi Y, Naito Y, Komatsu M.
Diabetol Metab Syndr · research-article; journal article · DOI 10.1186/s13098-016-0151-7Efficacy of lixisenatide in patients with type 2 diabetes: A post hoc analysis of patients with diverse β-cell function in the GetGoal-M and GetGoal-S trials.
Yabe D, Ambos A, Cariou B, Duvnjak L, Evans M, González-Gálvez G, Lin J, Nikonova EV, de Pablos-Velasco P, Yale JF, Ahrén B.
J Diabetes Complications · clinical trial, phase iii; randomized controlled trial; journal article · DOI 10.1016/j.jdiacomp.2016.05.018Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial.
Rosenstock J, Guerci B, Hanefeld M, Gentile S, Aronson R, Tinahones FJ, Roy-Duval C, Souhami E, Wardecki M, Ye J, Perfetti R, Heller S, GetGoal Duo-2 Trial Investigators.
Diabetes Care · randomized controlled trial; journal article · DOI 10.2337/dc16-0014Lixisenatide: A New Member of the Glucagon-Like Peptide 1 Receptor Agonist Class of Incretin Therapies.
Shaefer CF.
Clin Diabetes · research-article; journal article · DOI 10.2337/diaclin.34.2.81Treatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short-acting and other glucagon-like peptide-1 receptor agonists.
Giorgino F, Bonadonna RC, Gentile S, Vettor R, Pozzilli P.
Diabetes Metab Res Rev · research support, non-u.s. gov't; review-article; review; journal article · DOI 10.1002/dmrr.2775Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome.
Pfeffer MA, Claggett B, Probstfield JL.
N Engl J Med · letter; comment · DOI 10.1056/nejmc1600140Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome.
Tsutsumi Y, Tsujimoto Y, Ikenoue T.
N Engl J Med · letter; comment · DOI 10.1056/nejmc1600140Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome.
Derosa G, Maffioli P.
N Engl J Med · letter; comment · DOI 10.1056/nejmc1600140Lixisenatide in type 2 diabetes: latest evidence and clinical usefulness.
Anderson SL, Trujillo JM.
Ther Adv Chronic Dis · review-article; review; journal article · DOI 10.1177/2040622315609312Diabetes: Lixisenatide does not increase rates of CVD events.
Huynh K.
Nat Rev Cardiol · comment; journal article · DOI 10.1038/nrcardio.2015.199Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP, McMurray JJ, Probstfield JL, Riddle MC, Solomon SD, Tardif JC, ELIXA Investigators.
N Engl J Med · research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1056/nejmoa1509225Evaluation of the efficacy and safety of lixisenatide add-on treatment to basal insulin therapy among T2DM patients with different body mass indices from GetGoal trials.
Eto K, Naito Y, Seino Y.
Diabetol Metab Syndr · research-article; journal article · DOI 10.1186/s13098-015-0104-6Effect of the GLP-1 Receptor Agonist Lixisenatide on Counterregulatory Responses to Hypoglycemia in Subjects With Insulin-Treated Type 2 Diabetes.
Farngren J, Persson M, Ahrén B.
Diabetes Care · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.2337/dc15-1274Lixisenatide clinical experience on patients with type 2 diabetes and obesity in endocrinology offices in Malaga.
Roca-Rodríguez Mdel M, Tapia-Guerrero MJ, Maraver-Selfa S, Tinahones FJ, Mancha-Doblas I.
Endocrinol Nutr · letter; clinical trial; research support, non-u.s. gov't · DOI 10.1016/j.endonu.2015.07.004Long-term safety of once-daily lixisenatide in Japanese patients with type 2 diabetes mellitus: GetGoal-Mono-Japan.
Seino Y, Yabe D, Takami A, Niemoeller E, Takagi H.
J Diabetes Complications · clinical trial, phase iii; comparative study; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/j.jdiacomp.2015.07.003Cost-effectiveness of once daily GLP-1 receptor agonist lixisenatide compared to bolus insulin both in combination with basal insulin for the treatment of patients with type 2 diabetes in Norway.
Huetson P, Palmer JL, Levorsen A, Fournier M, Germe M, McLeod E.
J Med Econ · research support, non-u.s. gov't; journal article · DOI 10.3111/13696998.2015.1038271Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects.
Becker RH, Stechl J, Steinstraesser A, Golor G, Pellissier F.
Diabetes Metab Res Rev · research support, non-u.s. gov't; research-article; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1002/dmrr.2647Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial.
Meier JJ, Rosenstock J, Hincelin-Méry A, Roy-Duval C, Delfolie A, Coester HV, Menge BA, Forst T, Kapitza C.
Diabetes Care · comparative study; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.2337/dc14-1984Glucagon-like peptide-1 receptor agonists as insulin add-on therapy in patients with inadequate glycemic control in type 2 diabetes mellitus: lixisenatide as a new therapeutic option.
Gómez-Huelgas R, Azriel S, Puig-Domingo M, Vidal J, de Pablos-Velasco P.
Int J Clin Pharmacol Ther · research support, non-u.s. gov't; review; journal article · DOI 10.5414/cp202052Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo.
Bentley-Lewis R, Aguilar D, Riddle MC, Claggett B, Diaz R, Dickstein K, Gerstein HC, Johnston P, Køber LV, Lawson F, Lewis EF, Maggioni AP, McMurray JJ, Ping L, Probstfield JL, Solomon SD, Tardif JC, Wu Y, Pfeffer MA, ELIXA Investigators.
Am Heart J · comparative study; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/j.ahj.2015.02.002Efficacy and safety of lixisenatide in Japanese patients with type 2 diabetes mellitus inadequately controlled by sulfonylurea with or without metformin: Subanalysis of GetGoal-S.
Onishi Y, Niemoeller E, Ikeda Y, Takagi H, Yabe D, Seino Y.
J Diabetes Investig · research-article; journal article · DOI 10.1111/jdi.12275Efficacy and safety of lixisenatide in elderly (≥65 years old) and very elderly (≥75 years old) patients with type 2 diabetes: an analysis from the GetGoal phase III programme.
Raccah D, Miossec P, Esposito V, Niemoeller E, Cho M, Gerich J.
Diabetes Metab Res Rev · research support, non-u.s. gov't; journal article · DOI 10.1002/dmrr.2588Lixisenatide improves recognition memory and exerts neuroprotective actions in high-fat fed mice.
Lennox R, Flatt PR, Gault VA.
Peptides · research support, non-u.s. gov't; journal article · DOI 10.1016/j.peptides.2014.08.014The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus.
Christensen M, Miossec P, Larsen BD, Werner U, Knop FK.
Expert Opin Drug Discov · review; journal article · DOI 10.1517/17460441.2014.942638Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease.
McClean PL, Hölscher C.
Neuropharmacology · comparative study; research support, non-u.s. gov't; journal article · DOI 10.1016/j.neuropharm.2014.07.015